BTK and mantle cell lymphoma: In MCL, ibrutinib treatment impaired glycolysis in sensitive cells, whereas metabolic reprogramming to oxidative phosphorylation (OXPHOS) was associated with resistance to the BTK inhibitor [18, 19].